Clinicopathologic characteristics and prognostic factors of mucoepidermoid carcinoma: a 20-year real-world cohort study Authors: M.-C. Lin, X. Jiang, X. Xiao, Z.-C. Qiu, X. Zhou, X.-Y. Chen, X.-R. Li, X.-H. Wang, F. Han Published: 2026 ABSTRACT BackgroundThe purpose of this study was to characterize the clinicopathologic features, treatment patterns, long-term outcomes, and prognostic factors of mucoepidermoid carcinoma (MEC) in a real-world cohort.Materials and methodsWe retrospectively analyzed 283 patients with MEC treated between 2005 and 2025. Treatment included surgery, radiotherapy, and chemotherapy according to institutional protocols. Disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Independent prognostic factors were evaluated using Cox proportional hazards models.ResultsWith a median follow-up of 53 months (range 1-246), histological grading was available for 202 patients: 35.6% low-grade, 46.0% intermediate-grade, and 18.3% high-grade. The parotid gland (42.8%) and lung (19.4%) were the most common primary sites. Among 118 patients tested for cAMP response element–binding protein-regulated transcription coactivator 1/3–mastermind-like protein 2 (CRTC1/3–MAML2) fusion, 95 (80.5%) were fusion-positive, and fusion status was significantly associated with histological grade. Five-year DFS/OS rates were 100%/100% for low-grade, 88.2%/93.5% for intermediate-grade, and 70.7%/79.8% for high-grade tumors. High-grade tumors had significantly poorer survival than low- or intermediate-grade tumors, whereas low- and intermediate-grade tumors did not differ significantly, including after propensity score matching. Perineural invasion independently predicted DFS, whereas age, N classification, and primary site independently predicted OS.ConclusionsMEC showed marked prognostic heterogeneity by histological grade and primary site. Intermediate-grade MEC showed relatively favorable outcomes, but matched analyses were limited by small sample size and few events. CRTC1/3–MAML2 fusion was associated with histological grade, whereas its prognostic value remains exploratory. Introduction Mucoepidermoid carcinoma (MEC) is a rare malignant epithelial neoplasm composed of mucous, squamous, and intermediate cells. It most commonly arises in the salivary glands, accounting for 10%-15% of all salivary gland tumors and a substantial proportion of salivary gland malignancies.1 Although the salivary glands are the predominant site, MEC has also been reported in the lung, breast, and esophagus. Pulmonary MEC represents only 0.1%-0.2% of primary lung cancers,2,3 breast MEC accounts for 0.2%-0.3% of breast tumors,4,5 and esophageal MEC is exceedingly rare, comprising <1% of esophageal cancers.6,7 These patterns underscore the biological heterogeneity of MEC across organ systems. According to the 2022 World Health Organization (WHO) Classification of Head and Neck Tumors, MEC is categorized as low-, intermediate-, or high-grade based on cytologic atypia, architectural pattern, and cell composition, commonly referencing the Armed Forces Institute of Pathology (AFIP) or Brandwein systems.8, 9, 10, 11 Low-grade tumors typically exhibit cystic architecture and abundant mucous cells, whereas high-grade tumors display solid growth, marked atypia, necrosis, or perineural invasion (PNI). Despite the availability of multiple grading systems, substantial interobserver variability limits reproducibility.9, 10, 11, 12 A characteristic molecular feature of MEC is the t(11;19)(q21;p13) translocation that produces the cAMP response element–binding protein-regulated transcription coactivator 1/3–mastermind-like protein 2 (CRTC1/3–MAML2) fusion oncogene.13, 14, 15, 16 This fusion activates the cAMP response element–binding protein pathway and is highly specific for MEC, particularly low- and intermediate-grade tumors. Although earlier studies suggested an association with a favorable prognosis, more recent large-cohort analyses have not consistently confirmed its independent prognostic value.13, 14, 15, 16 Surgical resection with negative margins remains the primary treatment.17 Post-operative radiotherapy is recommended for patients with high-risk features such as PNI, nodal metastasis, extracapsular extension, or positive margins,17,18 whereas concurrent chemoradiotherapy (CCRT) has not demonstrated a clear survival advantage.19 Systemic therapies provide limited benefit and are generally reserved for recurrent or progressive disease. Although MEC most frequently arises in the salivary glands, rare cases in the lung, breast, and esophagus lack standardized treatment recommendations and are typically managed based on institutional experience.20,21 Previous large studies have mainly focused on salivary gland MEC or on the diagnostic and prognostic implications of CRTC1/3–MAML2 alterations. In contrast, the present study provides a 20-year real-world overview of MEC across diverse anatomical sites, including major and minor salivary glands, lung, and other rare primary locations. By integrating clinicopathologic characteristics, treatment patterns, site-specific outcomes, histological grade, PNI, and CRTC1/3–MAML2 status, this study aimed to clarify clinically relevant prognostic factors in routine practice rather than to establish a purely molecular or pathology-based classification. Materials and methods Study design and patients This was a retrospective, real-world cohort study based on consecutively treated patients in routine clinical practice. This study included patients with MEC treated at Sun Yat-sen University Cancer Center between January 2005 and May 2025. Eligible patients met the following inclusion criteria: (i) histopathological confirmation of a primary MEC, (ii) receipt of surgical resection and/or radiotherapy at our center, and (iii) no distant metastasis or recurrence at diagnosis. Patients with de novo distant metastasis, corresponding to M1 disease, were excluded; however, nonmetastatic stage IV disease caused by locally advanced T classification and/or regional nodal involvement was retained. Patients were excluded if they had (i) no available follow-up information after initial treatment, (ii) a history of other malignant tumors, or (iii) severe coexisting illness that precluded standard treatment or follow-up. Patients who died during follow-up were not excluded and were counted as events for overall survival (OS). The study was approved by the institutional ethics committee (approval number B2025-852-01), with a waiver of informed consent. The patient selection process is presented in Supplementary Figure S1 (available at https://doi.org/10.1016/j.esmorw.2026.100759). Histological grade Histological grading of MEC was carried out according to the 2022 WHO Classification of Head and Neck Tumours (5th edition),8 which classifies tumors as low-, intermediate-, or high-grade based on cytologic atypia, architectural configuration, and the relative proportions of mucous, squamous, and intermediate cells. For pulmonary MEC, the WHO Classification of Thoracic Tumors generally adopts a two-tier system (low versus high grade) that emphasizes cystic architecture, cytologic atypia, and mitotic activity.22,23 However, some studies still apply the traditional three-tier ‘salivary gland-type’ scheme to better capture histological heterogeneity.3,22,23 Mammary MEC is usually graded according to salivary-type criteria (WHO or AFIP), integrating cystic formation, mucinous differentiation, and cytologic atypia.5 Due to its rarity and the absence of a site-specific framework, esophageal MEC is typically graded by extrapolation from salivary or pulmonary systems and is often simplified into a two-tiered classification.6,7 To ensure consistency and comparability across different anatomical sites, all cases were uniformly evaluated using the WHO three-tiered grading system. All hematoxylin–eosin-stained slides were independently reviewed by two experienced pathologists, with consensus reached on final diagnosis. Treatment Treatment decisions were made according to routine clinical practice rather than protocol-driven trial settings. In this study, all patients received surgical resection, radiotherapy, or a combination of both at the primary tumor site, with a subset also receiving chemotherapy. Surgical approaches were determined by the attending surgeons based on a comprehensive evaluation, including medical history, clinical examination, imaging studies, and intraoperative findings. Radiotherapy planning and dose prescription were individualized by radiation oncologists, based on clinical history, operative reports, post-operative imaging, and pathological features. For head and neck MEC, prescribed doses ranged from 46.8 to 70 Gy, with most patients receiving 66 Gy in 30 fractions. Among patients with pulmonary MEC, only three underwent radiotherapy, with doses of 64 Gy (fractionation details unavailable), 69.7 Gy in 34 fractions, and 53.75 Gy in 25 fractions, respectively. Platinum-based chemotherapy regimens were used in patients with head and neck MEC. For pulmonary MEC, chemotherapy was administered according to the clinical physicians. Regimens included TP (paclitaxel + cisplatin), TC (paclitaxel + carboplatin), GP (gemcitabine + cisplatin), PN (pemetrexed + nedaplatin), AP (pemetrexed + cisplatin/carboplatin), and docetaxel + nedaplatin. Adjuvant treatment decisions were made by a multidisciplinary tumor board. Pathological risk factors assessed included tumor staging (T and N classification, overall stage), resection margin status, PNI, lymphovascular invasion (LVI), tumor grade, and the presence of CRTC1/3–MAML2 fusion. All patients completed their planned treatment regimens. End points The primary endpoint was disease-free survival (DFS), defined as the interval from the start of treatment to the first documented recurrence (local, regional, or distant). The secondary endpoint was OS, defined as the interval from treatment initiation to death from any cause. Statistical analysis Categorical variables were expressed as frequencies and percentages and compared using the chi-square test or two-tailed Fisher’s exact test, as appropriate. Survival outcomes, including DFS and OS, were estimated using the Kaplan–Meier method and compared with the log-rank test. Hazard ratios were calculated using univariate Cox proportional hazards models. Variables with P < 0.05 in univariate analysis were further incorporated into multivariate Cox regression models. To reduce confounding bias, propensity score matching (PSM) was carried out to compare patients between the low/intermediate-grade group and the intermediate/high-grade group at a 1 : 1 ratio. Matching covariates included age, smoking history, sex, T classification, N classification, overall stage, primary site, PNI, LVI, resection margin status, chemotherapy, and radiotherapy. For PSM, the caliper width was set at 0.05 of the standard deviation of the logit of the propensity score for the low/intermediate-grade comparison and 0.1 for the intermediate-/high-grade comparison. After matching, categorical variables were compared using the chi-square test or Fisher’s exact test as appropriate. All statistical analyses were two-sided, with a significance threshold of P < 0.05. Analyses were conducted using IBM SPSS Statistics, version 25.0 (IBM Corp, Armonk, New York). Results Clinical and pathological characteristics From January 2005 to May 2025, a total of 347 patients with a pathological diagnosis of MEC treated at our institution were screened in this study. The following patients were excluded: 19 with de novo distant metastasis or recurrence at diagnosis and 45 with no available follow-up information after initial treatment. Patients who died during follow-up were retained in the survival analyses. Ultimately, 283 patients were included in the analysis, comprising 134 males (47.3%) and 149 females (52.7%). The median age at diagnosis was 41 years (range, 5-77 years). Fifty-four patients (19.1%) had a history of smoking. The most common primary site was the parotid gland (n = 121, 42.8%), followed by the lung (n = 55, 19.4%), palate (n = 25, 8.8%), tongue (n = 12, 4.2%), and submandibular gland (n = 11, 3.9%). With respect to histological grade, 72 patients (25.4%) had low-grade disease, 93 (32.9%) had intermediate-grade disease, and 37 (13.1%) had high-grade disease. Regarding treatment, 164 patients (58.0%) underwent surgery alone, whereas 69 (24.4%) received surgery combined with radiotherapy. Detailed clinicopathologic characteristics of the cohort are summarized in Table 1. To further characterize real-world treatment patterns, treatment modalities were stratified by histological grade and American Joint Committee on Cancer stage, as shown in Supplementary Table S1 (available at https://doi.org/10.1016/j.esmorw.2026.100759).Table 1Baseline characteristics of included patientsCharacteristicsNumber of cases%Overall283100Patient characteristicsSex Male13447.35 Female14952.65Age, years (median 41, range 5-77) ≤5018665.72 >509734.28Smoke No22980.92 Yes5419.08Tumor characteristicsTumor size, cm (median 2.3, range 0.5-6) ≤29031.80 2-414450.88 >4238.13 Unknown269.19T classification 110537.1 28429.68 33311.66 45017.67 Unknown113.89N classification 024185.16 1207.07 2176.01 310.35 Unknown41.41AJCC stage I11640.99 II6221.91 III3412.01 IV5920.85 Unknown124.24Tumor grade Low7225.44 Intermediate9332.86 High3713.07 Unknown8128.62CRTC1/3-MAML2 Negative238.13 Positive9533.57 Unknown16558.3PNI No15053.0 Yes4315.19 Unknown9031.8LVI No18063.6 Yes103.53 Unknown9332.86Resection status R023382.33 R1-23412.01 Unknown165.65Primary site Parotid gland12142.76 Lung5519.43 Palate258.83 Tongue124.24 Submandibular gland113.89 Nasopharynx93.18 Oral floor51.77 Gum51.77 Maxillary sinus41.41 Maxilla41.41 Sublingual gland41.41 Bronchus41.41 Throat31.06 Nasal cavity20.71 Lip20.71 Oropharynx20.71 Retromolar triangle20.71 Trachea20.71 Mammary gland20.71 Esophagus20.71 Tonsil10.35 Cheek10.35 Submentum10.35 Bucca10.35 Lower jawbone10.35 Laryngopharynx10.35 Orbit10.35Treatment characteristicsTreatment Surgery16457.95 Surgery + radiotherapy6924.38 Surgery + chemotherapy103.53 Surgery + radiotherapy + chemotherapy3713.07 Radiotherapy + chemotherapy31.06Surgery No31.06 Yes28098.94Chemotherapy No23583.04 Yes4816.96Radiotherapy No17461.48 Yes10938.52AJCC, American Joint Committee on Cancer; CRTC1/3-MAML2, CREB-regulated transcription coactivator 1/3–mastermind-like transcriptional coactivator 2; LVI, lymphovascular invasion; PNI, perineural invasion; R0, complete resection; R1-2, microscopic or macroscopic positive. Table 1Baseline characteristics of included patientsCharacteristicsNumber of cases%Overall283100Patient characteristicsSex Male13447.35 Female14952.65Age, years (median 41, range 5-77) ≤5018665.72 >509734.28Smoke No22980.92 Yes5419.08Tumor characteristicsTumor size, cm (median 2.3, range 0.5-6) ≤29031.80 2-414450.88 >4238.13 Unknown269.19T classification 110537.1 28429.68 33311.66 45017.67 Unknown113.89N classification 024185.16 1207.07 2176.01 310.35 Unknown41.41AJCC stage I11640.99 II6221.91 III3412.01 IV5920.85 Unknown124.24Tumor grade Low7225.44 Intermediate9332.86 High3713.07 Unknown8128.62CRTC1/3-MAML2 Negative238.13 Positive9533.57 Unknown16558.3PNI No15053.0 Yes4315.19 Unknown9031.8LVI No18063.6 Yes103.53 Unknown9332.86Resection status R023382.33 R1-23412.01 Unknown165.65Primary site Parotid gland12142.76 Lung5519.43 Palate258.83 Tongue124.24 Submandibular gland113.89 Nasopharynx93.18 Oral floor51.77 Gum51.77 Maxillary sinus41.41 Maxilla41.41 Sublingual gland41.41 Bronchus41.41 Throat31.06 Nasal cavity20.71 Lip20.71 Oropharynx20.71 Retromolar triangle20.71 Trachea20.71 Mammary gland20.71 Esophagus20.71 Tonsil10.35 Cheek10.35 Submentum10.35 Bucca10.35 Lower jawbone10.35 Laryngopharynx10.35 Orbit10.35Treatment characteristicsTreatment Surgery16457.95 Surgery + radiotherapy6924.38 Surgery + chemotherapy103.53 Surgery + radiotherapy + chemotherapy3713.07 Radiotherapy + chemotherapy31.06Surgery No31.06 Yes28098.94Chemotherapy No23583.04 Yes4816.96Radiotherapy No17461.48 Yes10938.52AJCC, American Joint Committee on Cancer; CRTC1/3-MAML2, CREB-regulated transcription coactivator 1/3–mastermind-like transcriptional coactivator 2; LVI, lymphovascular invasion; PNI, perineural invasion; R0, complete resection; R1-2, microscopic or macroscopic positive. Baseline characteristics of included patients AJCC, American Joint Committee on Cancer; CRTC1/3-MAML2, CREB-regulated transcription coactivator 1/3–mastermind-like transcriptional coactivator 2; LVI, lymphovascular invasion; PNI, perineural invasion; R0, complete resection; R1-2, microscopic or macroscopic positive. CRTC1/3–MAML2 fusion and tumor grade Among the 283 patients, 118 underwent molecular testing for CRTC1/3–MAML2 fusion, with 95 (80.5%) testing positive and 23 (19.5%) testing negative. As illustrated in Supplementary Table S2 (available at https://doi.org/10.1016/j.esmorw.2026.100759) fusion status was significantly correlated with histological grade (P < 0.05), with low- to intermediate-grade MEC showing a higher frequency of CRTC1/3–MAML2 fusion. Clinical outcomes The median follow-up duration for the 283 included patients was 53 months (range 1-246 months), with the last follow-up on 1 August 2025. During follow-up, 26 patients experienced disease progression, including 17 with local recurrence, 15 with regional recurrence, and 9 with distant metastasis. When stratified by primary tumor site, the 5-year DFS rates were 91.6% for the parotid gland, 95.7% for the lung, 75.0% for the trachea/larynx, 50.0% for the maxilla, and lowest for the tongue (45.5%); the 5-year OS rates were 96.8% for the parotid gland, 93.8% for the lung, 83.3% for the nasal cavity/paranasal sinus, 72.9% for the tongue, and lowest for the esophagus (0%). These site-specific survival outcomes are summarized in Supplementary Table S3 (available at https://doi.org/10.1016/j.esmorw.2026.100759). Among the two patients with esophageal MEC, both died during follow-up, with one dying from pneumonia and the other from cardiovascular disease. When stratified by histological grade, the 5-year DFS and OS rates for low-grade tumors were both 100%. For intermediate-grade tumors, the corresponding rates were 88.2% and 93.5%, respectively, whereas for high-grade tumors they were 70.7% and 79.8%, respectively. Pairwise comparisons revealed no significant differences between low- and intermediate-grade tumors for DFS or OS (both P > 0.05), whereas high-grade tumors showed significantly poorer DFS and OS compared with low- or intermediate-grade tumors (all P < 0.05). The Kaplan–Meier survival curves illustrating these grade-specific outcomes are shown in Figure 1A and B.Figure 1Kaplan–Meier curves for disease-free survival (DFS) and overall survival (OS) by histological grade. Kaplan–Meier survival curves for DFS and OS according to histological grade and pairwise matched comparisons. (A and B) Survival comparisons among low-, intermediate-, and high-grade tumors; (C and D) comparisons between low- and intermediate-grade tumors after propensity score matching (PSM); (E and F) comparisons between intermediate- and high-grade tumors after PSM. Kaplan–Meier curves for disease-free survival (DFS) and overall survival (OS) by histological grade. Kaplan–Meier survival curves for DFS and OS according to histological grade and pairwise matched comparisons. (A and B) Survival comparisons among low-, intermediate-, and high-grade tumors; (C and D) comparisons between low- and intermediate-grade tumors after propensity score matching (PSM); (E and F) comparisons between intermediate- and high-grade tumors after PSM. Intermediate-grade subgroup Pairwise subgroup analyses were further carried out according to histological grade. The baseline characteristics of patients in the low-grade versus intermediate-grade groups and intermediate-grade versus high-grade groups before and after PSM are summarized in Tables 2 and 3, respectively. After PSM, the DFS and OS rates between the low-grade and intermediate-grade groups did not remain significantly different (all P > 0.05; Figure 1C and D). Similarly, no significant differences were observed between the intermediate-grade and high-grade groups after PSM (all P > 0.05; Figure 1E and F). Given the small matched sample size, particularly in the intermediate- versus high-grade comparison, these matched analyses should be regarded as exploratory and may have been underpowered to detect clinically meaningful differences.Table 2Clinical characteristics of low-grade and intermediate-grade groups in the whole cohort and matched cohortVariablesThe entire cohortThe matched cohortLow-grade (n = 72)Intermediate-grade (n = 93)PSMDLow-grade (n = 47)Intermediate-grade(n = 47)PSMDAge, years, n (%)0.7690.517 ≤5048 (66.67)64 (68.82)0.04632 (68.09)29 (61.70)−0.131 >5024 (33.33)29 (31.18)−0.04615 (31.91)18 (38.30)0.131Smoke, n (%)0.4950.789 No61 (84.72)75 (80.65)−0.10338 (80.85)39 (82.98)0.057 Yes11 (15.28)18 (19.35)0.1039 (19.15)8 (17.02)−0.057Sex, n (%)0.2201.000 Female41 (56.94)44 (47.31)−0.19324 (51.06)24 (51.06)0.000 Male31 (43.06)49 (52.69)0.19323 (48.94)23 (48.94)0.000T classification, n (%)0.2841.000 T1-255 (78.57)64 (71.11)−0.16537 (78.72)37 (78.72)0.000 T3-415 (21.43)26 (28.89)0.16510 (21.28)10 (21.28)0.000N classification, n (%)0.2260.241 N0-171 (98.61)87 (93.55)−0.20647 (100.00)44 (93.62)−0.261 N2-31 (1.39)6 (6.45)0.2060 (0.00)3 (6.38)0.261Overall stage, n (%)0.1401.000 I-II52 (74.29)57 (63.33)−0.22735 (74.47)35 (74.47)0.000 III-IV18 (25.71)33 (36.67)0.22712 (25.53)12 (25.53)0.000Primary site, n (%)0.4950.804 Major salivary glands39 (54.17)43 (46.24)−0.15923 (48.94)20 (42.55)−0.129 Minor salivary glands18 (25.00)32 (34.41)0.19812 (25.53)13 (27.66)0.048 Lung13 (18.06)17 (18.28)0.00610 (21.28)13 (27.66)0.143 Others2 (2.78)1 (1.08)−0.1652 (4.26)1 (2.13)−0.147PNI, n (%)0.5190.272 No38 (77.55)56 (82.35)0.12637 (78.72)41 (87.23)0.255 Yes11 (22.45)12 (17.65)−0.12610 (21.28)6 (12.77)−0.255LVI, n (%)1.0001.000 No47 (97.92)67 (98.53)0.05146 (97.87)46 (97.87)0.000 Yes1 (2.08)1 (1.47)−0.0511 (2.13)1 (2.13)0.000Resection status, n (%)0.7300.536 R061 (87.14)75 (85.23)−0.05440 (85.11)42 (89.36)0.138 R1-29 (12.86)13 (14.77)0.0547 (14.89)5 (10.64)−0.138Chemotherapy, n (%)0.1221.000 No65 (90.28)76 (81.72)−0.22140 (85.11)40 (85.11)0.000 Yes7 (9.72)17 (18.28)0.2217 (14.89)7 (14.89)0.000Radiotherapy, n (%)0.3690.815 No49 (68.06)57 (61.29)−0.13934 (72.34)35 (74.47)0.049 Yes23 (31.94)36 (38.71)0.13913 (27.66)12 (25.53)−0.049LVI, lymphovascular invasion; PNI, perineural invasion; R0, complete resection; R1-2, microscopic or macroscopic positive; SMD, standardized mean difference.Table 3Clinical characteristics of intermediate-grade and high-grade groups in the whole cohort and matched cohortVariablesThe entire cohortThe matched cohortIntermediate-grade (n = 93)High-grade (n = 37)PSMDIntermediate-grade (n = 20)High-grade (n = 20)PSMDAge, years, n (%)0.015a1.000 ≤5064 (68.82)17 (45.95)−0.45910 (50.00)10 (50.00)0.000 >5029 (31.18)20 (54.05)0.45910 (50.00)10 (50.00)0.000Smoke, n (%)0.1101.000 No75 (80.65)25 (67.57)−0.27912 (60.00)12 (60.00)0.000 Yes18 (19.35)12 (32.43)0.2798 (40.00)8 (40.00)0.000Sex, n (%)0.4840.337 Female44 (47.31)15 (40.54)−0.13810 (50.00)7 (35.00)−0.314 Male49 (52.69)22 (59.46)0.13810 (50.00)13 (65.00)0.314T classification, n (%)0.033a0.752 T1-264 (71.11)19 (51.35)−0.39511 (55.00)10 (50.00)−0.100 T3-426 (28.89)18 (48.65)0.3959 (45.00)10 (50.00)0.100N classification, n (%)0.003a1.000 N0-187 (93.55)27 (72.97)−0.46317 (85.00)16 (80.00)−0.125 N2-36 (6.45)10 (27.03)0.4633 (15.00)4 (20.00)0.125Overall stage, n (%)0.0711.000 I-II57 (63.33)17 (45.95)−0.34911 (55.00)11 (55.00)0.000 III-IV33 (36.67)20 (54.05)0.3499 (45.00)9 (45.00)0.000Primary site, n (%)0.8500.749 Major salivary glands43 (46.24)16 (43.24)−0.0609 (45.00)6 (30.00)−0.327 Minor salivary glands32 (34.41)14 (37.84)0.0715 (25.00)8 (40.00)0.306 Lung17 (18.28)6 (16.22)−0.0565 (25.00)5 (25.00)0.000 Others1 (1.08)1 (2.70)0.1001 (5.00)1 (5.00)0.000PNI, n (%)0.006a1.000 No56 (82.35)18 (56.25)−0.52612 (60.00)12 (60.00)0.000 Yes12 (17.65)14 (43.75)0.5268 (40.00)8 (40.00)0.000LVI, n (%)0.001a1.000 No67 (98.53)23 (76.67)−0.51719 (95.00)19 (95.00)0.000 Yes1 (1.47)7 (23.33)0.5171 (5.00)1 (5.00)0.000Resection status, n (%)0.7901.000 R075 (85.23)30 (83.33)−0.05115 (75.00)16 (80.00)0.125 R1-213 (14.77)6 (16.67)0.0515 (25.00)4 (20.00)−0.125Chemotherapy, n (%)0.032a0.723 No76 (81.72)23 (63.89)−0.37114 (70.00)15 (75.00)0.115 Yes17 (18.28)13 (36.11)0.3716 (30.00)5 (25.00)−0.115Radiotherapy, n (%)0.2440.342 No57 (61.29)18 (50.00)−0.2269 (45.00)12 (60.00)0.306 Yes36 (38.71)18 (50.00)0.22611 (55.00)8 (40.00)−0.306LVI, lymphovascular invasion; PNI, perineural invasion; R0, complete resection; R1-2, microscopic or macroscopic positive; SMD, standardized mean difference.aStatistically significant difference (P < 0.05). Table 2Clinical characteristics of low-grade and intermediate-grade groups in the whole cohort and matched cohortVariablesThe entire cohortThe matched cohortLow-grade (n = 72)Intermediate-grade (n = 93)PSMDLow-grade (n = 47)Intermediate-grade(n = 47)PSMDAge, years, n (%)0.7690.517 ≤5048 (66.67)64 (68.82)0.04632 (68.09)29 (61.70)−0.131 >5024 (33.33)29 (31.18)−0.04615 (31.91)18 (38.30)0.131Smoke, n (%)0.4950.789 No61 (84.72)75 (80.65)−0.10338 (80.85)39 (82.98)0.057 Yes11 (15.28)18 (19.35)0.1039 (19.15)8 (17.02)−0.057Sex, n (%)0.2201.000 Female41 (56.94)44 (47.31)−0.19324 (51.06)24 (51.06)0.000 Male31 (43.06)49 (52.69)0.19323 (48.94)23 (48.94)0.000T classification, n (%)0.2841.000 T1-255 (78.57)64 (71.11)−0.16537 (78.72)37 (78.72)0.000 T3-415 (21.43)26 (28.89)0.16510 (21.28)10 (21.28)0.000N classification, n (%)0.2260.241 N0-171 (98.61)87 (93.55)−0.20647 (100.00)44 (93.62)−0.261 N2-31 (1.39)6 (6.45)0.2060 (0.00)3 (6.38)0.261Overall stage, n (%)0.1401.000 I-II52 (74.29)57 (63.33)−0.22735 (74.47)35 (74.47)0.000 III-IV18 (25.71)33 (36.67)0.22712 (25.53)12 (25.53)0.000Primary site, n (%)0.4950.804 Major salivary glands39 (54.17)43 (46.24)−0.15923 (48.94)20 (42.55)−0.129 Minor salivary glands18 (25.00)32 (34.41)0.19812 (25.53)13 (27.66)0.048 Lung13 (18.06)17 (18.28)0.00610 (21.28)13 (27.66)0.143 Others2 (2.78)1 (1.08)−0.1652 (4.26)1 (2.13)−0.147PNI, n (%)0.5190.272 No38 (77.55)56 (82.35)0.12637 (78.72)41 (87.23)0.255 Yes11 (22.45)12 (17.65)−0.12610 (21.28)6 (12.77)−0.255LVI, n (%)1.0001.000 No47 (97.92)67 (98.53)0.05146 (97.87)46 (97.87)0.000 Yes1 (2.08)1 (1.47)−0.0511 (2.13)1 (2.13)0.000Resection status, n (%)0.7300.536 R061 (87.14)75 (85.23)−0.05440 (85.11)42 (89.36)0.138 R1-29 (12.86)13 (14.77)0.0547 (14.89)5 (10.64)−0.138Chemotherapy, n (%)0.1221.000 No65 (90.28)76 (81.72)−0.22140 (85.11)40 (85.11)0.000 Yes7 (9.72)17 (18.28)0.2217 (14.89)7 (14.89)0.000Radiotherapy, n (%)0.3690.815 No49 (68.06)57 (61.29)−0.13934 (72.34)35 (74.47)0.049 Yes23 (31.94)36 (38.71)0.13913 (27.66)12 (25.53)−0.049LVI, lymphovascular invasion; PNI, perineural invasion; R0, complete resection; R1-2, microscopic or macroscopic positive; SMD, standardized mean difference. Clinical characteristics of low-grade and intermediate-grade groups in the whole cohort and matched cohort LVI, lymphovascular invasion; PNI, perineural invasion; R0, complete resection; R1-2, microscopic or macroscopic positive; SMD, standardized mean difference. Table 3Clinical characteristics of intermediate-grade and high-grade groups in the whole cohort and matched cohortVariablesThe entire cohortThe matched cohortIntermediate-grade (n = 93)High-grade (n = 37)PSMDIntermediate-grade (n = 20)High-grade (n = 20)PSMDAge, years, n (%)0.015a1.000 ≤5064 (68.82)17 (45.95)−0.45910 (50.00)10 (50.00)0.000 >5029 (31.18)20 (54.05)0.45910 (50.00)10 (50.00)0.000Smoke, n (%)0.1101.000 No75 (80.65)25 (67.57)−0.27912 (60.00)12 (60.00)0.000 Yes18 (19.35)12 (32.43)0.2798 (40.00)8 (40.00)0.000Sex, n (%)0.4840.337 Female44 (47.31)15 (40.54)−0.13810 (50.00)7 (35.00)−0.314 Male49 (52.69)22 (59.46)0.13810 (50.00)13 (65.00)0.314T classification, n (%)0.033a0.752 T1-264 (71.11)19 (51.35)−0.39511 (55.00)10 (50.00)−0.100 T3-426 (28.89)18 (48.65)0.3959 (45.00)10 (50.00)0.100N classification, n (%)0.003a1.000 N0-187 (93.55)27 (72.97)−0.46317 (85.00)16 (80.00)−0.125 N2-36 (6.45)10 (27.03)0.4633 (15.00)4 (20.00)0.125Overall stage, n (%)0.0711.000 I-II57 (63.33)17 (45.95)−0.34911 (55.00)11 (55.00)0.000 III-IV33 (36.67)20 (54.05)0.3499 (45.00)9 (45.00)0.000Primary site, n (%)0.8500.749 Major salivary glands43 (46.24)16 (43.24)−0.0609 (45.00)6 (30.00)−0.327 Minor salivary glands32 (34.41)14 (37.84)0.0715 (25.00)8 (40.00)0.306 Lung17 (18.28)6 (16.22)−0.0565 (25.00)5 (25.00)0.000 Others1 (1.08)1 (2.70)0.1001 (5.00)1 (5.00)0.000PNI, n (%)0.006a1.000 No56 (82.35)18 (56.25)−0.52612 (60.00)12 (60.00)0.000 Yes12 (17.65)14 (43.75)0.5268 (40.00)8 (40.00)0.000LVI, n (%)0.001a1.000 No67 (98.53)23 (76.67)−0.51719 (95.00)19 (95.00)0.000 Yes1 (1.47)7 (23.33)0.5171 (5.00)1 (5.00)0.000Resection status, n (%)0.7901.000 R075 (85.23)30 (83.33)−0.05115 (75.00)16 (80.00)0.125 R1-213 (14.77)6 (16.67)0.0515 (25.00)4 (20.00)−0.125Chemotherapy, n (%)0.032a0.723 No76 (81.72)23 (63.89)−0.37114 (70.00)15 (75.00)0.115 Yes17 (18.28)13 (36.11)0.3716 (30.00)5 (25.00)−0.115Radiotherapy, n (%)0.2440.342 No57 (61.29)18 (50.00)−0.2269 (45.00)12 (60.00)0.306 Yes36 (38.71)18 (50.00)0.22611 (55.00)8 (40.00)−0.306LVI, lymphovascular invasion; PNI, perineural invasion; R0, complete resection; R1-2, microscopic or macroscopic positive; SMD, standardized mean difference.aStatistically significant difference (P < 0.05). Clinical characteristics of intermediate-grade and high-grade groups in the whole cohort and matched cohort LVI, lymphovascular invasion; PNI, perineural invasion; R0, complete resection; R1-2, microscopic or macroscopic positive; SMD, standardized mean difference. Statistically significant difference (P < 0.05). Univariate and multivariate analyses Univariable and multivariable analyses of risk factors for DFS and OS are summarized in Table 4. For DFS, significant predictors included age, T stage, N stage, histological grade, PNI, and LVI. For OS, age, T stage, N stage, histological grade, primary tumor site, and PNI were identified as significant prognostic factors. In multivariable analyses, PNI emerged as an independent prognostic factor for DFS, whereas age, N stage, and primary tumor site were independent prognostic factors for OS.Table 4Univariate and multivariate analysis of risk factors for DFS and OSVariablesUnivariable analysisMultivariable analysisPHR (95% CI)PHR (95% CI)DFSAge, years ≤501.00 (reference)1.00 (reference) >500.001a3.61 (1.65-7.88)0.0642.90 (0.94-8.96)Smoke No1.00 (reference) Yes0.2891.60 (0.67-3.80)Sex Female1.00 (reference) Male0.6310.83 (0.38-1.80)T classification T1-21.00 (reference)1.00 (reference) T3-4<0.001a5.07 (2.17-11.86)0.6771.31 (0.37-4.59)N classification N0-11.00 (reference)1.00 (reference) N2-30.005a4.07 (1.52-10.85)0.1292.81 (0.74-10.68)Tumor grade Low/intermediate1.00 (reference)1.00 (reference) High0.003a3.70 (1.57-8.71)0.5961.36 (0.44-4.21)CRTC1/3–MAML2 Negative1.00 (reference) Positive0.0620.28 (0.08-1.06)Primary site Major salivary glands1.00 (reference) Minor salivary glands0.1541.81 (0.80-4.11) Lung0.2370.40 (0.09-1.82) Others0.6221.68 (0.22-13.05)PNI No1.00 (reference)1.00 (reference) Yes<0.001a6.20 (2.48-15.50)0.005a6.28 (1.75-22.47)LVI No1.00 (reference)1.00 (reference) Yes0.023a4.18 (1.22-14.37)0.7421.27 (0.30-5.32)Resection status R01.00 (reference) R1-20.3501.68 (0.57-4.95)OSAge, years ≤501.00 (reference)1.00 (reference) >50<0.001a9.88 (3.27-29.89)0.013a8.48 (1.56-46.17)Smoke No1.00 (reference) Yes0.0542.50 (0.98-6.35)Sex Female1.00 (reference) Male0.2991.62 (0.65-4.03)T classification T1-21.00 (reference)1.00 (reference) T3-40.004a4.34 (1.60-11.74)0.8720.87 (0.16-4.71)N classification N0-11.00 (reference)1.00 (reference) N2-3<0.001a7.90 (2.96-21.07)0.013a7.34 (1.51-35.65)Tumor grade Low/intermediate1.00 (reference)1.00 (reference) High<0.001a6.27 (2.23-17.65)0.5301.55 (0.39-6.10)CRTC1/3–MAML2 Negative1.00 (reference) Positive0.4770.37 (0.02-5.85)Primary site Major salivary glands1.00 (reference)1.00 (reference) Minor salivary glands0.0882.65 (0.86-8.10)0.2432.93 (0.48-17.83) Lung0.7041.32 (0.31-5.54)0.016a24.52 (1.81-332.89) Others0.001a10.25 (2.44-43.04)0.037a7.89 (1.13-55.08)PNI No1.00 (reference)1.00 (reference) Yes0.002a5.33 (1.84-15.43)0.0509.41 (1.01-88.43)LVI No1.00 (reference) Yes0.1273.21 (0.72-14.33)Resection status R01.00 (reference) R1-20.5560.54 (0.07-4.14)CRTC1/3-MAML2, CREB-regulated transcription coactivator 1/3–mastermind-like transcriptional coactivator 2; DFS, disease-free survival; LVI, lymphovascular invasion; OS, overall survival; PNI, perineural invasion; R0, complete resection; R1-2, microscopic or macroscopic positive.aStatistically significant difference (P < 0.05). Table 4Univariate and multivariate analysis of risk factors for DFS and OSVariablesUnivariable analysisMultivariable analysisPHR (95% CI)PHR (95% CI)DFSAge, years ≤501.00 (reference)1.00 (reference) >500.001a3.61 (1.65-7.88)0.0642.90 (0.94-8.96)Smoke No1.00 (reference) Yes0.2891.60 (0.67-3.80)Sex Female1.00 (reference) Male0.6310.83 (0.38-1.80)T classification T1-21.00 (reference)1.00 (reference) T3-4<0.001a5.07 (2.17-11.86)0.6771.31 (0.37-4.59)N classification N0-11.00 (reference)1.00 (reference) N2-30.005a4.07 (1.52-10.85)0.1292.81 (0.74-10.68)Tumor grade Low/intermediate1.00 (reference)1.00 (reference) High0.003a3.70 (1.57-8.71)0.5961.36 (0.44-4.21)CRTC1/3–MAML2 Negative1.00 (reference) Positive0.0620.28 (0.08-1.06)Primary site Major salivary glands1.00 (reference) Minor salivary glands0.1541.81 (0.80-4.11) Lung0.2370.40 (0.09-1.82) Others0.6221.68 (0.22-13.05)PNI No1.00 (reference)1.00 (reference) Yes<0.001a6.20 (2.48-15.50)0.005a6.28 (1.75-22.47)LVI No1.00 (reference)1.00 (reference) Yes0.023a4.18 (1.22-14.37)0.7421.27 (0.30-5.32)Resection status R01.00 (reference) R1-20.3501.68 (0.57-4.95)OSAge, years ≤501.00 (reference)1.00 (reference) >50<0.001a9.88 (3.27-29.89)0.013a8.48 (1.56-46.17)Smoke No1.00 (reference) Yes0.0542.50 (0.98-6.35)Sex Female1.00 (reference) Male0.2991.62 (0.65-4.03)T classification T1-21.00 (reference)1.00 (reference) T3-40.004a4.34 (1.60-11.74)0.8720.87 (0.16-4.71)N classification N0-11.00 (reference)1.00 (reference) N2-3<0.001a7.90 (2.96-21.07)0.013a7.34 (1.51-35.65)Tumor grade Low/intermediate1.00 (reference)1.00 (reference) High<0.001a6.27 (2.23-17.65)0.5301.55 (0.39-6.10)CRTC1/3–MAML2 Negative1.00 (reference) Positive0.4770.37 (0.02-5.85)Primary site Major salivary glands1.00 (reference)1.00 (reference) Minor salivary glands0.0882.65 (0.86-8.10)0.2432.93 (0.48-17.83) Lung0.7041.32 (0.31-5.54)0.016a24.52 (1.81-332.89) Others0.001a10.25 (2.44-43.04)0.037a7.89 (1.13-55.08)PNI No1.00 (reference)1.00 (reference) Yes0.002a5.33 (1.84-15.43)0.0509.41 (1.01-88.43)LVI No1.00 (reference) Yes0.1273.21 (0.72-14.33)Resection status R01.00 (reference) R1-20.5560.54 (0.07-4.14)CRTC1/3-MAML2, CREB-regulated transcription coactivator 1/3–mastermind-like transcriptional coactivator 2; DFS, disease-free survival; LVI, lymphovascular invasion; OS, overall survival; PNI, perineural invasion; R0, complete resection; R1-2, microscopic or macroscopic positive.aStatistically significant difference (P < 0.05). Univariate and multivariate analysis of risk factors for DFS and OS CRTC1/3-MAML2, CREB-regulated transcription coactivator 1/3–mastermind-like transcriptional coactivator 2; DFS, disease-free survival; LVI, lymphovascular invasion; OS, overall survival; PNI, perineural invasion; R0, complete resection; R1-2, microscopic or macroscopic positive. Statistically significant difference (P < 0.05). Discussion MEC is a rare malignancy with substantial biological and anatomical heterogeneity, and its prognostic determinants remain incompletely understood. Although previous large cohorts have provided important insights into salivary gland MEC, histological grade, and CRTC1/3–MAML2 alterations, evidence remains limited regarding real-world treatment patterns and outcomes across different primary sites. The main contribution of our study is therefore not simply cohort size, but the integration of long-term clinical outcomes, anatomical site, treatment modality, histological grade, PNI, and molecular status in a consecutive real-world cohort. Low-grade MEC exhibited excellent prognosis, with 5-year DFS and OS both reaching 100%. Conversely, high-grade tumors showed markedly poorer outcomes, with 5-year DFS of 70.7% and OS of 79.8%. Intermediate-grade tumors demonstrated 5-year DFS and OS of 88.2% and 93.5%, respectively. Previous studies have yielded inconsistent conclusions—some proposed intermediate-grade tumors resemble low-grade disease biologically,5,6,17,24 whereas others reported survival patterns closer to high-grade disease.14,15,19 In our cohort, intermediate-grade MEC showed numerically favorable survival and did not differ significantly from low-grade MEC in pairwise and matched comparisons. However, the absence of statistical significance should not be interpreted as definitive biological equivalence, particularly given the limited number of matched patients and survival events. The matched comparison between intermediate- and high-grade tumors was especially underpowered, and therefore, these findings should be considered exploratory. Current grading systems, including AFIP, Brandwein, and WHO, differ in their thresholds for mitotic activity, necrosis, and cystic composition, which may lead to inconsistent classification of intermediate-grade tumors.9, 10, 11, 12 For example, the Brandwein system tends to up-classify certain intermediate-grade lesions as high-grade, whereas the WHO system is more lenient. These discrepancies underscore the need for a refined grading framework that integrates both histopathological and molecular parameters (e.g. MAML2 fusion status) to enhance reproducibility and prognostic accuracy. Surgical resection with negative margins remains the cornerstone of MEC management.17 Adjuvant radiotherapy is recommended for patients with PNI, nodal metastasis, extracapsular extension, or positive margins.17,18 Current evidence indicates that CCRT provides no significant survival benefit over radiotherapy alone and thus should not be routinely used outside prospective studies or multidisciplinary consensus.19 In our study, low-grade tumors were effectively managed with surgery alone, whereas high-grade disease frequently required combined adjuvant radiotherapy, consistent with guideline recommendations.17,18 The optimal management of intermediate-grade MEC remains controversial, particularly regarding elective neck dissection and post-operative radiotherapy.25 Our findings suggest that some intermediate-grade MECs without adverse pathological features may have relatively favorable outcomes. However, given the retrospective design, limited event number, and small matched cohorts, treatment de-escalation for intermediate-grade MEC should not be inferred from this study alone. Decisions regarding adjuvant therapy should continue to consider anatomical site, margin status, PNI, nodal involvement, and multidisciplinary assessment. Consistent with previous reports,13, 14, 15, 16 MAML2 fusion was detected in 80.5% (95/118) of tested patients, predominantly in low-grade and intermediate-grade tumors. Although highly specific for diagnosis, MAML2 fusion was not an independent prognostic factor, consistent with multi-institutional analyses.13, 14, 15, 16 Moreover, recent genomic studies have identified recurrent alterations involving the Notch signaling pathway, tumor protein p53 (TP53) mutations, and epidermal growth factor receptor amplification, which may drive tumor progression and serve as potential therapeutic targets.26, 27, 28 Incorporating these molecular markers into future risk models may further improve prognostic precision and inform therapeutic decision-making. Marked survival variations were also observed across primary sites. MECs of the parotid gland and lung exhibited favorable outcomes, with 5-year DFS and OS exceeding 90%, whereas tumors of the tongue, maxilla, nasal cavity/paranasal sinus, and trachea/larynx showed significantly worse prognosis. These differences may reflect surgical complexity, challenges in achieving negative margins, and a higher prevalence of high-grade histology in these locations.20,21,29,30 Therefore, both anatomical site and tumor grade should be considered in treatment planning. Current international guidelines (e.g. American Society of Clinical Oncology, European Society for Medical Oncology, and National Comprehensive Cancer Network) provide general recommendations for salivary gland malignancies but lack MEC-specific guidance, particularly regarding intermediate-grade tumors.17,18,31 Our data suggest that intermediate-grade MEC without adverse features may have relatively favorable outcomes, but this observation should not be interpreted as evidence supporting routine treatment de-escalation. Tumors in surgically challenging sites or with high-risk pathology require individualized multidisciplinary evaluation. As a retrospective single-center study, this research has inherent limitations, including potential selection and information biases. Some patients received initial treatment elsewhere, which may have affected treatment consistency and grading accuracy. Additionally, the exclusive use of WHO criteria limits direct comparison with studies employing AFIP or Brandwein systems. Finally, certain subgroups—particularly tongue MEC (n = 12, >30% high-grade)—had small sample sizes, which may have inflated observed associations between tumor site and prognosis. These findings highlight the need for validation in larger, multicenter prospective cohorts. Conclusion In this 20-year real-world cohort, MEC showed marked prognostic heterogeneity according to histological grade and primary site. Low-grade tumors had excellent outcomes, whereas high-grade tumors were associated with poorer DFS and OS. Intermediate-grade MEC showed relatively favorable outcomes, but the absence of significant differences from low-grade disease should be interpreted cautiously because of the limited matched sample size and event numbers. PNI independently predicted DFS, whereas age, N classification, and primary site independently predicted OS. CRTC1/3–MAML2 fusion was associated with histological grade, but its prognostic value remains exploratory. Larger multicenter studies are needed to validate these findings and refine risk-adapted management for MEC.